Ad
related to: statin and breastfeeding statistics
Search results
Results From The WOW.Com Content Network
Use during pregnancy may harm the baby and use during breastfeeding is not recommended. [3] It works by decreasing the liver's ability to produce cholesterol by blocking the enzyme HMG-CoA reductase. [2] Lovastatin was patented in 1979 and approved for medical use in 1987. [4] It is on the World Health Organization's List of Essential Medicines ...
Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins.
The Lancet's editorial position is that the data for Crestor's superiority rely too much on extrapolation from the lipid profile data (surrogate end-points) and too little on hard clinical end-points, which are available for other statins that had been on the market longer. The manufacturer responded by stating that few drugs had been tested so ...
Data-driven parenting guru Emily Oster and pediatric nutritionist Nicole Silber shed some light on the breastfeeding vs. formula feeding debate.
Breastfeeding data in the U.S. is currently collected by the CDC [Centers for Disease Control and Prevention], but those data stop at 12 months,” Meek says. “Changing the recommendations to ...
However, data (post hoc analysis) on atorvastatin has revealed that it may still be beneficial in reducing combined cardiac events, cardiac and all-cause mortality in those with a higher baseline LDL cholesterol >3.75 mmol/L. [50] [unreliable medical source] While the SHARP study suggested that LDL cholesterol-lowering treatments (e.g. statin ...
The government agency is tightening its standards for "healthy" claims. And for the first time in 30 years, its labeling rules will be updated to reflect new nutrition standards.
A systematic review concluded that while clinical trial meta-analyses underestimate the rate of muscle pain associated with statin use, the rates of rhabdomyolysis are still "reassuringly low" and similar to those seen in clinical trials (about 1–2 per 10,000 person years). [74]